軟骨素 Chondroitin
C 2 U 1
適應症與證據等級
法規與權威立場 (L4)
L4a · US FDA
立場：cautious
FDA has no questions regarding Gnosis S.P.A.'s conclusion that chondroitin sulfate sodium is generally recognized as safe under its intended conditions of use.
來源 ↗ L4b · EU EFSA
立場：against
L4c · UK NHS
立場：against
GPs no longer prescribe chondroitin and glucosamine on the NHS because there's no strong evidence that they are effective as a treatment. NICE recommends that they should not routinely be offered on the NHS.
來源 ↗ L4d · TW TFDA / 衛福部
立場：neutral
軟骨素在我國以及美國都不能取得藥品使用許可，祇能當作保健食品來販售。目前並沒有嚴謹的臨床試驗，可以證實軟骨素用於治療膝關節炎的療效。
來源 ↗ L4e · WHO
立場：not_addressed
市場與行銷 (L10)
L10a · TW Market Channels
硫酸軟骨素600mg×120顆
L10b · TW Legal Identity (TFDA)
食品不得為醫療效能之標示、宣傳或廣告
L10c · TW Community (PTT/Dcard/Mobile01)
保養品只能說輔助